Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2021

View Archived Issues

New clotting cofactor-binding anticoagulant RNA aptamers presented

Enanta Pharmaceuticals synthesizes new anti-HBV compounds

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent AKT1/AKT2/AKT3 inhibitors

New GABA(A) receptor agonists described by Sumitomo Dainippon Pharma

New antibacterials discovered at Merck & Co.

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical patent A2A/A2B receptor antagonists

New HIF-2alpha inhibitors discovered at Arcus Biosciences

DPX-SurMAGE dual T-cell therapy targeting MAGE-A9 and survivin shows promise in animal studies

Presepsin levels may be associated with COVID-19 mortality

Pharmacogenetic study identifies FKBP5 gene variants linked to treatment-resistant depression

SBIR grant supports POP Biotechnologies' development of theramostable vaccine for COVID-19

Mirati Therapeutics describes discovery and activity of GTPase KRAS inhibitor MRTX-1133

Recombinant AAVs for targeted gene delivery to muscle identified by a directed evolution approach

Filling the glass by emptying cancer cells' plates

Glycogen phosphorylase identified as a therapeutic target for anaplastic thyroid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...